Equities research analysts forecast that Veru Inc (NASDAQ:VERU) will report earnings per share (EPS) of ($0.04) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Veru’s earnings. Veru posted earnings per share of ($0.15) during the same quarter last year, which suggests a positive year over year growth rate of 73.3%. The company is scheduled to announce its next earnings report on Tuesday, August 13th.
On average, analysts expect that Veru will report full-year earnings of ($0.17) per share for the current fiscal year, with EPS estimates ranging from ($0.18) to ($0.17). For the next financial year, analysts forecast that the company will report earnings of ($0.12) per share, with EPS estimates ranging from ($0.14) to ($0.10). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Veru.
Veru (NASDAQ:VERU) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.01). The business had revenue of $6.98 million for the quarter, compared to analyst estimates of $6.98 million. Veru had a negative return on equity of 64.91% and a negative net margin of 91.61%.
Several equities analysts have recently issued reports on VERU shares. HC Wainwright boosted their price objective on Dova Pharmaceuticals from $18.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Cantor Fitzgerald started coverage on Veru in a research report on Monday, July 1st. They set an “overweight” rating and a $6.00 price objective for the company. ValuEngine downgraded Yext from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 10th. Finally, Zacks Investment Research upgraded Hope Bancorp from a “sell” rating to a “hold” rating in a research report on Wednesday, April 17th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $4.67.
In other Veru news, insider Mitchell Shuster Steiner sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $2.25, for a total value of $45,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 60,000 shares of company stock valued at $113,200 over the last 90 days. 29.50% of the stock is currently owned by insiders.
Large investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in shares of Veru during the 1st quarter valued at $95,000. BlackRock Inc. lifted its position in shares of Veru by 9.3% during the 4th quarter. BlackRock Inc. now owns 128,766 shares of the company’s stock valued at $180,000 after acquiring an additional 10,956 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Veru by 115.4% during the 4th quarter. Geode Capital Management LLC now owns 215,601 shares of the company’s stock valued at $301,000 after acquiring an additional 115,506 shares during the last quarter. Institutional investors own 8.85% of the company’s stock.
Shares of NASDAQ VERU traded down $0.06 during midday trading on Friday, hitting $2.13. 148,093 shares of the company’s stock were exchanged, compared to its average volume of 248,527. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.99 and a current ratio of 1.25. The business’s 50 day moving average is $2.13. The stock has a market cap of $137.51 million, a price-to-earnings ratio of -5.46 and a beta of 0.46. Veru has a twelve month low of $1.18 and a twelve month high of $2.49.
Veru Company Profile
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Featured Article: Earnings Per Share
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.